+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
PHP93: Development of Biosimilar Mark in EU-5 and USA
Home
Publications
PHP93: Development of Biosimilar Mark in EU-5 and USA
Back Home
PHP93: Development of Biosimilar Mark in EU-5 and USA
2012
Ammar, H. | Remuzat, C. | Houas, M. | Toumi, M. |
Volume: 15, Issue: 7, Pages: A305,
https://www.doi.org/10.1016/j.jval.2012.08.635
The website uses cookies.
Learn More
Ok
